|
市場調査レポート
商品コード
1593527
心臓バイオマーカーの市場規模・シェア・成長分析 (製品別、用途別、検査場所別、地域別)：産業予測 (2024～2031年)Cardiac Biomarkers Market Size, Share, Growth Analysis, By Product (Troponin, CK-MB), By Application (Acute Coronary Syndrome, Myocardial Infarction), By Location of Testing, By Region - Industry Forecast 2024-2031 |
||||||
|
|||||||
| 心臓バイオマーカーの市場規模・シェア・成長分析 (製品別、用途別、検査場所別、地域別)：産業予測 (2024～2031年) |
|
出版日: 2024年11月11日
発行: SkyQuest
ページ情報: 英文 199 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界の心臓バイオマーカーの市場規模は、2022年に94億2,000万米ドルと評価され、2023年の106億1,000万米ドルから2031年には275億6,000万米ドルに成長し、予測期間 (2024～2031年) に12.67%のCAGRで成長する見通しです。
心臓バイオマーカー市場は、心臓病の有病率の上昇、早期診断の利点に対する意識の高まり、個別化医療に対する需要の高まりに後押しされ、大幅な成長を遂げようとしています。心不全や心臓発作を含む様々な心臓疾患の診断と管理において、心臓へのストレスや損傷時に血流中に放出されるバイオマーカーは重要な役割を果たします。バイオマーカー検出の技術進歩が市場拡大をさらに刺激しています。しかし課題も依然として残っており、特に高度なバイオマーカー検査はコストが高く、標準化が進んでいないため検査結果にばらつきが生じる可能性があります。このような障壁にもかかわらず、市場全体の見通しは依然として楽観的です。これは、現在進行中の技術革新、予防医療への強い関心、医療費の高騰が原動力となっています。情勢が進展するにつれて、循環器疾患との闘いにおける効果的な診断ソリューションに対する需要の高まりに対応するため、心臓バイオマーカー業界は安定化し、成長すると予想されます。
目次
イントロダクション
- 調査の目的
- 定義
- 市場範囲
調査手法
- 情報調達
- 二次データソースと一次データソース
- 市場規模予測
- 市場の想定と制限
エグゼクティブサマリー
- 市場概要見通し
- 供給需要動向分析
- セグメント別機会分析
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- ポーターの分析
主な市場の考察
- 主な成功要因
- 競合の程度
- 主な投資機会
- 市場のエコシステム
- 技術分析
- 特許分析
- バリューチェーン分析
- 規制分析
心臓バイオマーカー市場：製品別
- 市場概要
- トロポニン
- CK-MB
- ミオグロビン
- BNP・NT-proBNP
- その他
心臓バイオマーカー市場：用途別
- 市場概要
- 急性冠症候群
- 心筋梗塞
- うっ血性心不全
- その他
心臓バイオマーカー市場：検査場所別
- 市場概要
- 臨床検査
- PoC (ポイントオブケア) 検査
心臓バイオマーカー市場：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ
- 中東・アフリカ (MEA)
- 湾岸協力会議 (GCC) 諸国
- 南アフリカ
- その他中東・アフリカ
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング (2023年)
- 主な市場企業が採用した戦略
- 市場における最近の活動
- 主要企業の市場シェア (2023年)
主要企業プロファイル
- Abbott
- QuidelOrtho Corporation
- Siemens AG
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Biomerieux SA
- Bio-Rad Laboratories, Inc.
- Randox Laboratories Ltd.
- Creative Diagnostics
- Life Diagnostics
- Thermo Fisher Scientific
- Becton, Dickinson and Company
- DiaSorin
- Myriad RBM
- Mindray Medical International Limited
- ReLIA Diagnostic Systems
- Merck KGaA
- Quanterix Corporation
- Eurofins Scientific
- Inova Diagnostics
Global Cardiac Biomarkers Market size was valued at USD 9.42 billion in 2022 and is poised to grow from USD 10.61 billion in 2023 to USD 27.56 billion by 2031, growing at a CAGR of 12.67% during the forecast period (2024-2031).
The cardiac biomarkers market is poised for considerable growth, propelled by a rising prevalence of heart diseases, heightened awareness about the advantages of early diagnosis, and an increasing demand for personalized medicine. These biomarkers, released into the bloodstream during heart stress or damage, play a crucial role in diagnosing and managing various cardiac disorders, including heart failure and heart attacks. Technological advancements in biomarker detection are further stimulating market expansion. However, challenges persist, notably the high costs of advanced biomarker tests and a lack of standardization, which can result in inconsistencies in test outcomes. Despite these hurdles, the overall market outlook remains optimistic, driven by ongoing innovations, a strong focus on preventive healthcare, and escalating healthcare expenditures. As the landscape evolves, the cardiac biomarkers sector is expected to stabilize and thrive, catering to an increasing demand for effective diagnostic solutions in the fight against cardiovascular diseases.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cardiac Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Cardiac Biomarkers Market Segmental Analysis
Global Cardiac Biomarkers Market is segmented by Product, Application, Location of Testing, and Region. Based on Product, the market is segmented into Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others. Based on Application, the market is segmented into Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Others. Based on Location of Testing, the market is segmented into Laboratory Testing, Point of Care Testing. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Cardiac Biomarkers Market
The increasing emphasis on preventive healthcare and early diagnosis is a significant market driver for the global cardiac biomarkers market. As healthcare systems worldwide shift from reactive to proactive approaches, there is a growing demand for innovative diagnostic tools that can identify cardiovascular diseases at an early stage. This trend is fueled by rising awareness about heart disease prevalence and the economic burden associated with late-stage interventions. Moreover, advancements in biomarker technology and the integration of personalized medicine enable healthcare providers to offer tailored treatment plans, further promoting demand for cardiac biomarkers, thereby driving market growth.
Restraints in the Global Cardiac Biomarkers Market
One of the significant market restraints for the global cardiac biomarkers market is the ongoing challenges related to biomarker reliability and validation. The complexity of the biological processes involved in cardiovascular diseases makes it difficult to ensure that biomarkers are consistently reliable across diverse populations and clinical settings. This lack of standardization can lead to variability in test results, which hinders the widespread adoption of these diagnostic tools. Furthermore, regulatory hurdles and the lengthy validation process for new biomarkers can delay market entry and contribute to costly investments, ultimately restricting innovation and limiting the growth potential of the cardiac biomarkers sector.
Market Trends of the Global Cardiac Biomarkers Market
The Global Cardiac Biomarkers market is experiencing a notable trend towards the adoption of multi-biomarker panels, reflecting a shift from traditional single biomarker assessments. This approach allows for comprehensive evaluation of cardiovascular risk factors, encompassing stress, cardiac injury, and inflammation. As healthcare providers increasingly recognize the limitations of individual biomarkers, multi-biomarker methodologies are being explored to enhance risk stratification, particularly in complex cases where single markers may fall short. This trend is expected to drive innovation and growth in the market, as the demand for more accurate and holistic cardiovascular diagnostics continues to escalate.
Table of Contents
Introduction
- Objectives of the Study
- Definitions
- Market Scope
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Market Overview Outlook
- Supply Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factor
- Degree of Competition
- Top Investment Pockets
- Ecosystem of the Market
- Technology Analysis
- Patent Analysis
- Value Chain Analysis
- Regulatory Analysis
Cardiac Biomarkers Market By Product
- Market Overview
- Troponin
- CK-MB
- Myoglobin
- BNP & NT-proBNP
- Others
Cardiac Biomarkers Market By Application
- Market Overview
- Acute Coronary Syndrome
- Myocardial Infarction
- Congestive Heart Failure
- Others
Cardiac Biomarkers Market By Location of Testing
- Market Overview
- Laboratory Testing
- Point of Care Testing
Cardiac Biomarkers Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2023
- Strategies Adopted by Key Market Players
- Recent Activities in the Market
- Key Companies Market Share (%), 2023
Key Company Profiles
- Abbott
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- QuidelOrtho Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Siemens AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Danaher Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biomerieux SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Randox Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Creative Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Life Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Becton, Dickinson and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- DiaSorin
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Myriad RBM
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mindray Medical International Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ReLIA Diagnostic Systems
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck KGaA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Quanterix Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eurofins Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Inova Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
